Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 24.42 AUD -1.57% Market Closed
Market Cap: 8.2B AUD

Intrinsic Value

The intrinsic value of one TLX stock under the Base Case scenario is 22.78 AUD. Compared to the current market price of 24.42 AUD, Telix Pharmaceuticals Ltd is Overvalued by 7%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TLX Intrinsic Value
22.78 AUD
Overvaluation 7%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Telix Pharmaceuticals Ltd

TLX
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for TLX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Telix Pharmaceuticals Ltd
ASX:TLX
AU
Biotechnology
Market Cap
8.2B AUD
IPO
Nov 15, 2017
AU
Biotechnology
Market Cap
8.2B AUD
IPO
Nov 15, 2017
Price
AU$false
EPS
AU$false
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Telix’s reliance on complex radiopharmaceutical manufacturing and distribution channels introduces significant logistical and cost risks, potentially limiting timely and efficient market penetration.

Bull Theses

Telix’s portfolio of targeted radiopharmaceuticals addresses high-unmet-need oncology indications, positioning the firm for rapid market adoption if efficacy and safety data continue to be strong.

Show More Less
How do you feel about TLX?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Telix Pharmaceuticals Ltd
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Telix Pharmaceuticals Ltd

Current Assets 918.6m
Cash & Short-Term Investments 710.3m
Receivables 149m
Other Current Assets 59.3m
Non-Current Assets 597.9m
Long-Term Investments 56.1m
PP&E 54.3m
Intangibles 416.1m
Other Non-Current Assets 71.3m
Efficiency

Free Cash Flow Analysis
Telix Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Telix Pharmaceuticals Ltd

Revenue
783.2m AUD
Cost of Revenue
-299.3m AUD
Gross Profit
483.9m AUD
Operating Expenses
-404m AUD
Operating Income
79.9m AUD
Other Expenses
-30m AUD
Net Income
49.9m AUD
Fundamental Scores

TLX Profitability Score
Profitability Due Diligence

Telix Pharmaceuticals Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
ROE is Increasing
43/100
Profitability
Score

Telix Pharmaceuticals Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

TLX Solvency Score
Solvency Due Diligence

Telix Pharmaceuticals Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Negative Net Debt
Long-Term Solvency
55/100
Solvency
Score

Telix Pharmaceuticals Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TLX Price Targets Summary
Telix Pharmaceuticals Ltd

Wall Street analysts forecast TLX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TLX is 33.13 AUD with a low forecast of 25.25 AUD and a high forecast of 37.8 AUD.

Lowest
Price Target
25.25 AUD
3% Upside
Average
Price Target
33.13 AUD
36% Upside
Highest
Price Target
37.8 AUD
55% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Telix Pharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for TLX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

TLX Insider Trading
Buy and sell transactions by insiders

TLX News

Other Videos
What is the Intrinsic Value of one TLX stock?

The intrinsic value of one TLX stock under the Base Case scenario is 22.78 AUD.

Is TLX stock undervalued or overvalued?

Compared to the current market price of 24.42 AUD, Telix Pharmaceuticals Ltd is Overvalued by 7%.

Back to Top